Biodexa Pharmaceuticals Plc (BDRX) stock
BDRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới năm tài chính 2025, năm kết thúc ngày Dec 31, 2025Last filing: 20-F on Mar 27, 2026Score 1/30
$2.14−0.10 (-4.46%)
Close on Nov 17, 2026Market cap $4.83MP/E –Yield –
Biodexa Pharmaceuticals r&d expenses
Research and development expenses are spending on new products and technology.
For fiscal 2025 it was £3.96M, down 27.1% from the year before. Over ten years it grew -7.6% a year on average. The highest annual figure on record is £9.36M in fiscal 2018.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | £3.96M | -27.1% |
| FY2024 | Dec 31, 2024 | £5.44M | +33.7% |
| FY2023 | Dec 31, 2023 | £4.07M | -20.4% |
| FY2022 | Dec 31, 2022 | £5.11M | +9.8% |
| FY2021 | Dec 31, 2021 | £4.65M | -23.3% |
| FY2020 | Dec 31, 2020 | £6.07M | -22.6% |
| FY2019 | Dec 31, 2019 | £7.84M | -16.2% |
| FY2018 | Dec 31, 2018 | £9.36M | +12.4% |
| FY2017 | Dec 31, 2017 | £8.33M | +7.7% |
| FY2016 | Dec 31, 2016 | £7.73M | -11.3% |
| FY2015 | Dec 31, 2015 | £8.71M | – |
See a number that looks wrong?